Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 3/20 | 0.35 |
| ▸ | JAK1 | P23458 | 3/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.34 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785218 | 0.90 | GPR119 (0.39) | GPR119CTSSJAK2JAK1USP30 | |
| SCHEMBL785217 | 0.90 | GPR119 (0.39) | GPR119CTSSJAK2JAK1USP30 | |
| SCHEMBL785344 | 0.88 | PSMB11 (0.36) | CTSSJAK2JAK1NPY5RPRMT3 | |
| SCHEMBL784656 | 0.88 | ABL1 (0.40) | CTSSNPY5RPRMT3F10WDR5 | |
| SCHEMBL803662 | 0.86 | TLR9 (0.39) | GPR119CTSSJAK2JAK1USP30 | |
| SCHEMBL785229 | 0.86 | HCRTR1 (0.36) | CTSSJAK2JAK1PRMT3MCHR1 | |
| SCHEMBL785215 | 0.86 | CTSS (0.41) | CTSSPRMT3F10WDR5 | |
| SCHEMBL785873 | 0.85 | DRD2 (0.39) | CTSSJAK2JAK1NPY5RPRMT3 | |
| SCHEMBL785020 | 0.85 | POLB (0.38) | CTSSJAK2JAK1PRMT3WDR5 | |
| SCHEMBL803454 | 0.85 | CTSS (0.41) | GPR119CTSSJAK2JAK1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | GPR119 698/4885CTSS 824/4885JAK2 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.